HRP20050787A2 - Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid - Google Patents

Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid

Info

Publication number
HRP20050787A2
HRP20050787A2 HR20050787A HRP20050787A HRP20050787A2 HR P20050787 A2 HRP20050787 A2 HR P20050787A2 HR 20050787 A HR20050787 A HR 20050787A HR P20050787 A HRP20050787 A HR P20050787A HR P20050787 A2 HRP20050787 A2 HR P20050787A2
Authority
HR
Croatia
Prior art keywords
fluoroanilino
chloro
methyl
phenylacetic acid
pharmaceutical composition
Prior art date
Application number
HR20050787A
Other languages
English (en)
Croatian (hr)
Inventor
Forenzo Patrick
Y. Khaled Maha
Wang Barbara
Lawrence Zielinski Joseph
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050787(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20050787A2 publication Critical patent/HRP20050787A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HR20050787A 2003-03-12 2005-09-08 Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid HRP20050787A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12
PCT/EP2004/002528 WO2004080451A1 (en) 2003-03-12 2004-03-11 Pharmaceutical composition comprising 5-methyl-2-2’-(chloro-6’-fluoroanilino) phe nylacetic acid

Publications (1)

Publication Number Publication Date
HRP20050787A2 true HRP20050787A2 (en) 2006-12-31

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050787A HRP20050787A2 (en) 2003-03-12 2005-09-08 Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid

Country Status (30)

Country Link
US (2) US20060094787A1 (xx)
EP (1) EP1603550B1 (xx)
JP (1) JP4580921B2 (xx)
KR (1) KR20050109077A (xx)
CN (1) CN100345536C (xx)
AR (1) AR043536A1 (xx)
AT (1) ATE418332T1 (xx)
AU (1) AU2004218921B2 (xx)
BR (1) BRPI0408270A (xx)
CA (1) CA2518393A1 (xx)
CL (1) CL2004000496A1 (xx)
DE (1) DE602004018622D1 (xx)
EC (1) ECSP055998A (xx)
ES (1) ES2318277T3 (xx)
HK (1) HK1086492A1 (xx)
HR (1) HRP20050787A2 (xx)
IL (1) IL170518A (xx)
IS (1) IS2658B (xx)
MA (1) MA27670A1 (xx)
MX (1) MXPA05009686A (xx)
MY (1) MY139455A (xx)
NO (1) NO20054662L (xx)
NZ (1) NZ542218A (xx)
PE (1) PE20041063A1 (xx)
PT (1) PT1603550E (xx)
RU (1) RU2363462C2 (xx)
TN (1) TNSN05222A1 (xx)
TW (1) TWI327913B (xx)
WO (1) WO2004080451A1 (xx)
ZA (1) ZA200506750B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2541265A1 (en) * 2003-10-08 2005-04-28 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
MX2010005198A (es) * 2007-11-12 2010-05-20 Novartis Ag Composiciones liquidas que comprenden valsartan.
EP2926810A1 (en) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of loxoprofen
WO2017218894A1 (en) * 2016-06-16 2017-12-21 Cutispharma, Inc. Composition and method for proton pump inhibitor suspension
CN109922801B (zh) 2016-09-09 2023-07-18 库蒂斯制药公司 甲硝唑和巴氯芬的混悬剂和稀释剂
EP3655418A4 (en) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. METHOD OF TREATMENT OF GLIOBLASTOMA
EP3687501A4 (en) * 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) * 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
MXPA04006482A (es) * 2002-01-07 2004-10-04 Pharmacia Corp Mezcla de farmacos con velocidad de disolucion mejorada.
AU2003223491A1 (en) * 2002-04-05 2003-10-27 Nitromed, Inc. Nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
PT1603550E (pt) 2009-03-20
TWI327913B (en) 2010-08-01
JP2006519811A (ja) 2006-08-31
ES2318277T3 (es) 2009-05-01
DE602004018622D1 (de) 2009-02-05
PE20041063A1 (es) 2005-03-07
ZA200506750B (en) 2007-02-28
EP1603550B1 (en) 2008-12-24
MA27670A1 (fr) 2005-12-01
NZ542218A (en) 2009-01-31
MXPA05009686A (es) 2005-10-20
WO2004080451A1 (en) 2004-09-23
CL2004000496A1 (es) 2005-01-14
IL170518A (en) 2010-11-30
CN100345536C (zh) 2007-10-31
RU2363462C2 (ru) 2009-08-10
CN1756541A (zh) 2006-04-05
KR20050109077A (ko) 2005-11-17
HK1086492A1 (en) 2006-09-22
NO20054662L (no) 2005-12-05
IS8049A (is) 2005-09-28
IS2658B (is) 2010-08-15
TNSN05222A1 (en) 2007-06-11
ATE418332T1 (de) 2009-01-15
NO20054662D0 (no) 2005-10-11
RU2005131310A (ru) 2006-05-10
MY139455A (en) 2009-10-30
EP1603550A1 (en) 2005-12-14
ECSP055998A (es) 2006-01-27
US20060094787A1 (en) 2006-05-04
AR043536A1 (es) 2005-08-03
CA2518393A1 (en) 2004-09-23
US20090048344A1 (en) 2009-02-19
AU2004218921A1 (en) 2004-09-23
AU2004218921B2 (en) 2007-05-17
BRPI0408270A (pt) 2006-03-07
JP4580921B2 (ja) 2010-11-17
TW200505429A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
HRP20050787A2 (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid
DK1435909T3 (da) Stabil sammensætning indeholdende partikler i en frossen vandig matrix
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
ATE402929T1 (de) Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
HRP20050123B1 (hr) Kompozicija i antivirusna aktivnost supstituiranih azaindoloksooctenih piperazin derivata
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
DE602004019405D1 (de) Pharmazeutische zubereitungen
BRPI0607413A2 (pt) composição farmacêutica compreendendo derivados de indolilmaleimida
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
BR0211995A (pt) Preparados de combinação de derivados de propanolamina substituìdos por arila com outras substâncias ativas e sua aplicação
DE50115451D1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
HRP20050603A2 (en) Novel anticonvulsant derivative salts
ATE402158T1 (de) Flavonoid-derivat
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
NO20060743L (no) Nasal farmasoytisk sammensetning av piribedil
DK1631574T3 (da) Colchicosidanaloge
BRPI0411524A (pt) formulação farmacêutica de amoxicilina e clavulanato, uso de carboximetilcelulose de sódio, e, método de tratar infecção bacteriana em pacientes pediátricos
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
ATE464896T1 (de) Zubereitung enthaltend oxidierte flavonoid- derivate
ATE394386T1 (de) 2-phenylpyran-4-on-derivate als selektive cox-2 inhibitoren
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110308

Year of fee payment: 8

OBST Application withdrawn